title: Rapid decline in HIV viral load when introducing raltegravir-containing antiretroviral treatment late in pregnancy.
abstract: Antenatal screening program for HIV has been in use in Sweden since 1987 with a 95-98% acceptance rate. Screening is performed during gestational week 10-12 and antiretroviral treatment (ART) to prevent mother-to-child transmission (MTCT) is initiated at gestational week 14-18. However, some women present with HIV in late pregnancy and additional treatment are wanted to achieve viral suppression before delivery. The integrase inhibitor raltegravir has a favorable pharmacokinetic profile and a capacity to rapidly decrease the viral load (VL). We describe four women presenting as HIV positive late in pregnancy, their ART, and outcome for the mother and child. Four women were discovered as HIV positive late in pregnancy, of 7 discovered in the antenatal screening programme in Stockholm County Council during 2011. Raltegravir was added to standard ART. The mean VL at presentation was 217,000 copies per milliliter (range, 65,000-637,000). A rapid decline of HIV RNA was observed in all cases, one woman treated with ART for only 8 days prior to delivery. The mean VL decline per week was 1.12 log (range, 0.94-1.22), which is estimated to occur (based on literature) after 1-2 months with standard ART. No side effects due to raltegravir were observed in mothers or infants. Caesarean section was performed in all cases, and the women did not breastfeed. No infant was infected. This report suggests that raltegravir added to standard antiretroviral treatment would be an option for women presenting with HIV in late pregnancy.
authors.affiliation: Department of Medicine, Division of Infectious Diseases, Karolinska Institutet Stockholm, Sweden.
authors.forename: Katarina
authors.initials: K
authors.lastname: Westling
authors.forename: Karin
authors.initials: K
authors.lastname: Pettersson
authors.forename: Anneli
authors.initials: A
authors.lastname: Kaldma
authors.forename: Lars
authors.initials: L
authors.lastname: Navér
mesh_terms: D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001942:Breast Feeding / Q000706:statistics & numerical data*; D002585:Cesarean Section / Q000706:statistics & numerical data; D004334:Drug Administration Schedule; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011760:Pyrrolidinones / Q000008:administration & dosage* / Q000494:pharmacology; D000068898:Raltegravir Potassium; D013548:Sweden / Q000453:epidemiology; D013997:Time Factors; D019562:Viral Load / Q000187:drug effects*
chemical_list: D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium